Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension (PAH)
Effects of UE Aerobic Exercise on Exercise Capacity and PA in Patients With Pulmonary Arterial Hypertension.
Group A will be training group and group B will be control group. Deep breathing exercises will be done as baseline treatment in both groups.
- Trial name
- NCT05947240
- Testing
- aerobic exercises, active alternating movements for the upper limbs
- Where
- Pakistan
- Volunteers
- 26 people
- Sponsor
- Riphah International University
Pulmonary Arterial Hypertension (PAH), Premature Infants
PNEUMOSTEM® for Improving Respiratory Outcomes in Very Premature Infants Diagnosed With Early Pulmonary Arterial Hypertension
The goal of this clinical trial is to evaluate the safety and potential efficacy of PNEUMOSTEM® for improving respiratory outcomes in very premature infants diagnosed with Early Pulmonary Arterial Hypertension.
- Trial name
- REVIVE-PH (NCT07368088)
- Testing
- PNEUMOSTEM®
- Where
- South Korea
- Volunteers
- 12 people
- Sponsor
- Samsung Medical Center
Pulmonary Arterial Hypertension PAH
Home Rehabilitation Improves Cardiac Effort in Pulmonary Arterial Hypertension
The purpose of this study is to evaluate whether a home rehabilitation program for patients diagnosed with Pulmonary Arterial Hypertension (PAH) will decrease Cardiac Effort (number of heart beats used during 6-minute walk…
- Trial name
- NCT06477640
- Testing
- Exercise, Standard of Care
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Rochester
Pulmonary Arterial Hypertension (PAH)
Impact of Sotatercept on Pulmonary Artery and Right Ventricle Remodeling Imaging Assessed With 68Ga-FAPI PET/CT in Patients With PAH
Pulmonary arterial hypertension (PAH) is a rare, progressive disease characterized by structural changes in the pulmonary arteries, leading to increased pulmonary vascular resistance and elevated pulmonary arterial pressure and…
- Trial name
- SOFAPI (NCT07357974)
- Testing
- [68Ga]Ga-FAPI PET/CT, [68Ga]Ga-MAA PET/CT
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Brest
Heart Failure, Cardiomyopathies
Multimodal Physiologic State Intelligence Study
The OMNIPHYS study will investigate whether multimodal ultrasound and other routinely collected clinical and physiologic data can be combined with artificial intelligence to characterize changes in a person's physiologic state…
- Conditions
- Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute
- Trial name
- OMNIPHYS (NCT07814118)
- Testing
- OMNIPHYS Multimodal Ultrasound Imaging System
- Where
- United States
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Truway Health, Inc.
Pulmonary Arterial Hypertension
Pilot Study Evaluating the Safety and Performance of the GeNO NITROsyl Delivery System for Inhaled Nitric Oxide
This is an open label phase 2 pilot study designed to evaluate the safety, tolerability and device performance of the GeNO nitrosyl delivery system during right heart catheterization (RHC) in participants with pulmonary arterial…
- Trial name
- PILOT (NCT01092559)
- Testing
- Nitric Oxide generated by the GeNO nitrosyl delivery system
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Geno LLC
Pulmonary Arterial Hypertension
Safety and Efficacy of BIA 5-1058 in PAH
This study aims to assess the safety and tolerability of the individual highest tolerated zamicastat doses, achieved in the study BIA-51058-201, during long-term treatment in Pulmonary Arterial Hypertension (PAH) disease.
- Trial name
- NCT06009185
- Testing
- Oral zamicastat
- Where
- 11 sites in Austria, Germany and 4 more
- Volunteers
- 20 people
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension (PAH)
a Non-interventional Study of Sildenafil in the Treatment of Pulmonary Arterial Hypertension (PAH) in Adults From China
This observational study will involve analysis of data collected by the National Rare Disease Registry or medical records .The study will describe outcomes only in PAH(Pulmonary arterial hypertension) patients treated with…
- Trial name
- NCT05546125
- Testing
- as per Physician's prescription
- Where
- 7 sites in China
- Volunteers
- 100 people
- Sponsor
- Pfizer Pharmaceuticals Ltd.
Pulmonary Idiopathic Arterial Hypertension
Endothelial Progenitor Cells and Pulmonary Idiopathic Arterial Hypertension
Endothelial dysfunction ultimately represents an imbalance between the magnitude of injury and the capacity for repair. Current evidence established that endothelial progenitor cells (EPC) participate in several models of…
- Trial name
- NCT00551408
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Unidad de Investigacion Clinica en Medicina S.C.
Pulmonary Hypertension, Cardiovascular Diseases (CVD)
Pulmonary Arterial Hypertension and Associated Cardiovascular Disease Detection Using Artificial Intelligence
Cardiovascular disease (CVD) is a leading global cause of morbidity and mortality and excessive healthcare expenditures. Pulmonary hypertension (PH) represents an insidious and progressive subset of CVD affecting an estimated 1%…
- Trial name
- PULSAR (NCT07147725)
- Testing
- AI Stethoscope
- Where
- United Kingdom
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Hypertension, Pulmonary
Electronic Activity Level Monitoring Pilot in Pulmonary Hypertension
Evaluate the correlation between activity level (monitored by Fitbit Flex remote activity tracker) and 6-minute walk distance (6MWD) (performed by investigator) in patients with Pulmonary Arterial Hypertension (PAH) or Chronic…
- Trial name
- e-MOTION PH (NCT02536534)
- Testing
- Correlation assessment
- Where
- Canada
- Volunteers
- 35 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
An Open Label Access Study For Subjects Who Completed A1481156
The purpose of this study is to provide sildenafil therapy to subjects who have completed the A1481156 study for the treatment of Pulmonary Arterial Hypertension (PAH) in India and are judged by the Investigator to derive…
- Trial name
- NCT01582438
- Testing
- Access program - sildenafil citrate, Viagra, Revatio
- Where
- India
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension, Cardiovascular Diseases
Telerehabilitation Program Via Videoconference PAH - Randomized Clinical Trial
Pulmonary arterial hypertension (PAH) is a serious, progressive disease that causes pulmonary arterial pressure, significantly affecting functional capacity and quality of life.
- Conditions
- Pulmonary Arterial Hypertension, Cardiovascular Diseases, Respiratory Disease Nursing, Hypertension, Pulmonary
- Trial name
- NCT05655481
- Testing
- Aerobic and Resistance training with rehabilitation, Health education
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- University of Nove de Julho
Precapillary Pulmonary Hypertension, Pulmonary Arterial Hypertension
Evolution of Hypoxic Burden and Sympathetic/Parasympathetic Balance in Patients With Pulmonary Hypertension
Background and Rationale: Sleep-disordered breathing and nocturnal hypoxemia are highly prevalent in patients with precapillary pulmonary hypertension (PH), and current guidelines recommend systematic sleep assessment in this…
- Conditions
- Precapillary Pulmonary Hypertension, Pulmonary Arterial Hypertension, Sleep-disordered Breathing, Nocturnal Hypoxemia
- Trial name
- HRV&PH (NCT07464184)
- Testing
- Standard Clinical and Functional Assessment, Overnight Polysomnography
- Where
- France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Rouen
Pulmonary Arterial Hypertension, Pulmonary Arterial Remodeling
DNA Methylation Dynamics Underlying Arterial Remodeling in PAH Patients: CLEOPAHTRA Clinical Trial
To identify epigenetic-sensitive modifications and novel biomarkers linked to pathogenesis of pulmonary arterial hypertension (PAH), we will perform the first study analyzing differentially-methylated regions (DMRs) in…
- Trial name
- CLEOPAHTRA (NCT04282434)
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- University of Campania Luigi Vanvitelli
Pulmonary Vascular Disorder, Chronic Thromboembolic Pulmonary Hypertension
Exercise Performance on Ambient Air vs. Low-Flow Oxygen Therapy in Pulmonary Vascular Disease (PVD)
The investigators aim to study the effect of SOT in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).
- Conditions
- Pulmonary Vascular Disorder, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Arterial Hypertension
- Trial name
- NCT06384534
- Testing
- 6-minute walk distance (6MWD) test on ambient air, 6-minute walk distance test with supplemental oxygen
- Where
- Switzerland
- Volunteers
- 40 people
- Sponsor
- University of Zurich
Precapillary Pulmonary Hypertension
The Role of Trimetazidine on Right Ventricle Function in Pulmonary Arterial Hypertension
The study will evaluate the effect of trimetazidine versus placebo in addition to standard pulmonary arterial hypertension regime on right ventricular function in pulmonary arterial hypertension patients.
- Trial name
- TRIMETA-PH (NCT03273387)
- Testing
- Trimetazidine
- Where
- Indonesia
- Volunteers
- 26 people
- Sponsor
- Universitas Indonesia
Pulmonary Arterial Hypertension
Epoprostenol for Injection (EFI/ACT-385781A) - Pulmonary Arterial Hypertension
This study is investigating the effect of switching from Flolan® to Epoprostenol for Injection (EFI/ACT-385781A) in pulmonary arterial hypertension patients currently treated with Flolan®.
- Trial name
- EPITOME-2 (NCT01431716)
- Testing
- EFI/ACT-385781A
- Where
- 8 sites in Belgium, Canada and 4 more
- Volunteers
- 42 people
- Sponsor
- Actelion
Severe Pulmonary Arterial Hypertension
Open-label, Multi-center Protocol to Provide QTI571 to PAH Patients Who Participated in the Extension Study (A2301E1) in Japan
To provide continued treatment to Pulmonary Arterial Hypertension (PAH) patients who are benefitting from treatment with QTI571.
- Trial name
- NCT02042014
- Testing
- QTI571
- Where
- 3 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Pre-Pulmonary Atrial Hypertension
Ambrisentan for the Improvement in Right Ventricular Strain in Scleroderma Associated Pulmonary Arterial Hypertension
This research study is looking at the use of the drug ambrisentan and if it can improve right ventricle function in people with systemic sclerosis-associated pre-pulmonary arterial hypertension.
- Trial name
- AMERICA-PAH (NCT02169752)
- Testing
- Ambrisentan
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- National Jewish Health